These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23122361)

  • 1. Candidiasis and other oral mucosal lesions during and after interferon therapy for HCV-related chronic liver diseases.
    Nagao Y; Hashimoto K; Sata M
    BMC Gastroenterol; 2012 Nov; 12():155. PubMed ID: 23122361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exacerbation of oral lichen planus lesions during treatment of chronic hepatitis C with pegylated interferon and ribavirin.
    Grossmann Sde M; Teixeira R; de Aguiar MC; do Carmo MA
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):702-6. PubMed ID: 18679075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irsogladine maleate for the treatment of recurrent aphthous stomatitis in hepatitis C virus patients on pegylated-interferon and ribavirin: a pilot study.
    Hayashi N; George J; Shiroeda H; Saito T; Toshikuni N; Tsuchishima M; Arisawa T; Tsutsumi M
    J Gastroenterol Hepatol; 2013 Jun; 28(6):1015-8. PubMed ID: 23425065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features and management of oral lichen planus (OLP) with emphasis on the management of hepatitis C virus (HCV)-related OLP.
    Mester A; Lucaciu O; Ciobanu L; Apostu D; Ilea A; Campian RS
    Bosn J Basic Med Sci; 2018 Aug; 18(3):217-223. PubMed ID: 29984679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C.
    Comai S; Cavalletto L; Chemello L; Bernardinello E; Ragazzi E; Costa CV; Bertazzo A
    Pharmacol Res; 2011 Jan; 63(1):85-92. PubMed ID: 20940053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
    Berenguer J; González-García J; López-Aldeguer J; Von-Wichmann MA; Quereda C; Hernando A; Sanz J; Tural C; Ortega E; Mallolas J; Santos I; Miralles P; Montes ML; Bellón JM; Esteban H;
    J Antimicrob Chemother; 2009 Jun; 63(6):1256-63. PubMed ID: 19363085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI).
    Couzigou P; Pérusat S; Bourlière M; Trimoulet P; Poynard T; Leroy V; Marcellin P; Foucher J; Bronowicki JP; Chêne G;
    J Gastroenterol Hepatol; 2013 Feb; 28(2):329-34. PubMed ID: 23190183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection.
    Akhan SC; Kalender B; Ruzgar M
    Infection; 2008 Aug; 36(4):341-4. PubMed ID: 18629437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.
    Dieterich D; Rockstroh JK; Orkin C; Gutiérrez F; Klein MB; Reynes J; Shukla U; Jenkins A; Lenz O; Ouwerkerk-Mahadevan S; Peeters M; De La Rosa G; Tambuyzer L; Jessner W
    Clin Infect Dis; 2014 Dec; 59(11):1579-87. PubMed ID: 25192745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The influence of HCV infection and immunomodulating therapy (interferon-alpha and ribavirin) on the condition of minor salivary glands and oral mucosa].
    Sulka A; Simon K; Jeleń M; Piszko P
    Przegl Epidemiol; 2005; 59(2):455-66. PubMed ID: 16190554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exacerbation of oral erosive lichen planus by combination of interferon and ribavirin therapy for chronic hepatitis C.
    Nagao Y; Kawaguchi T; Ide T; Kumashiro R; Sata M
    Int J Mol Med; 2005 Feb; 15(2):237-41. PubMed ID: 15647837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
    Myers RP; Benhamou Y; Bochet M; Thibault V; Mehri D; Poynard T
    AIDS; 2004 Jan; 18(1):75-9. PubMed ID: 15090832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?
    Gluhovschi C; Gadalean F; Kaycsa A; Curescu M; Sporea I; Gluhovschi G; Petrica L; Velciov S; Bozdog G; Bob F; Vernic C; Cioca D
    Immunopharmacol Immunotoxicol; 2011 Dec; 33(4):744-50. PubMed ID: 21320001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C.
    Hu CC; Lin CL; Kuo YL; Chien CH; Chen SW; Yen CL; Lin CY; Chien RN
    Aliment Pharmacol Ther; 2013 Jan; 37(1):81-90. PubMed ID: 23121150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes?
    Mousa N; Besheer T; Gad Y; Elbendary A; Mokbel T; Abdel-Aziz A
    J Ocul Pharmacol Ther; 2013 Apr; 29(3):345-8. PubMed ID: 23113644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple therapy of interferon and ribavirin with zinc supplementation for patients with chronic hepatitis C: a randomized controlled clinical trial.
    Suzuki H; Takagi H; Sohara N; Kanda D; Kakizaki S; Sato K; Mori M;
    World J Gastroenterol; 2006 Feb; 12(8):1265-9. PubMed ID: 16534882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection].
    Cheong HR; Woo HY; Heo J; Yoon KT; Kim DU; Kim GH; Kang DH; Song GA; Cho M
    Korean J Hepatol; 2010 Mar; 16(1):38-48. PubMed ID: 20375641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan.
    Aziz H; Gil ML; Waheed Y; Adeeb U; Raza A; Bilal I; Athar MA
    Infect Genet Evol; 2011 Apr; 11(3):640-5. PubMed ID: 21316487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of response-guided therapy using pegylated interferon and ribavirin for chronic hepatitis C virus infection in patients on maintenance dialysis.
    Goel A; Bhadauria DS; Kaul A; Prasad N; Gupta A; Sharma RK; Rai P; Aggarwal R
    Nephrology (Carlton); 2017 Sep; 22(9):706-711. PubMed ID: 27286895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.